Address And Details

601 Congress Street , Boston, MA 02210-2805
Fund Manager Nathan Thooft
Manager Tenure 8 Years 4 Months

Strategy And Objective

To seek high total return until the fund's target retirement date, with a greater focus on income as the target date approaches. Total return, commonly understood as the combination of income and capital appreciation, includes interest, capital gains, dividends, and distributions realized over a given period of time. Under normal market conditions, the fund primarily invests its assets in underlying funds using an asset allocation strategy designed for investors expected to retire around the year 2035. The portfolio managers of the fund allocate assets among the underlying funds according to an asset allocation strategy that becomes increasingly conservative over time. John Hancock Retirement Choices at 2035 Portfolio, which is designed for investors planning to retire around the year 2035, has a target asset allocation of 75.5% of its assets in underlying funds that invest primarily in equity securities. The fund will have greater exposure to underlying funds that invest primarily in equity securities than will a John Hancock Retirement Choices Portfolio with a closer target date. Over time, the asset allocation strategy will change according to a predetermined "glide path" shown in the following chart. As the glide path shows, the fund's asset mix becomes more conservative as time elapses. This reflects the desire to reduce investment risk and volatility as retirement approaches.

Net Asset Value

as of 5:23 PM ET 09/17/2021

Performance

  • 1 Week
  • -0.38%
  • 1 Month
  • +0.25%
  • 3 Months
  • +2.26%
  • 1 Yr Return
  • +14.64%
  • 5 Yr Return
  • +15.73%

Equity Sector Breakdown

Finance 93.20%
ConsumerDurables n/a
Energy n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Other 92.30%
Stocks 0.90%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 100.00 K

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -1.24 -1.27 n/a
Beta 0.68 0.67 n/a
R Squared 0.96 0.95 n/a
Std Deviation 12.90 10.40 n/a
Sharpe Ratio 0.86 1.00 n/a

Purchase Information

as of 5:19 PM ET 09/16/2021
Minimum Initial $0
Minimum Additional $0
Minimum Initial IRA $0

Performance

Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 06/30/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 06/30/2021
1 Year
  • +18.86%
  • +25.12%
+18.86% +25.12%
3 Year
  • +11.39%
  • +11.70%
+11.39% +11.70%
10 Year
  • n/a
  • n/a
n/a n/a
Life Of Fund
  • +9.37%
  • +9.26%
+9.37% +9.26%

Top 10 Holdings

Symbol Company Name % Of Assets
0P0000VD J HANCOCK 2 STRATEGIC EQ ALLO 56.28%
VCIT VANGUARD INTERM TRM CORP BD E 4.84%
HYLB XTRACKERS USD HI YLD CORP BD 4.29%
VWOB VANGUARD EM MKT GOVT BD ETF 3.38%
VO VANGUARD MID CAP ETF 2.79%
BND VANGUARD TOT BOND MKT IDX ETF 14.54%
VOO VANGUARD S&P 500 ETF 1.30%
ACWV ISHARES MSCI GL MIN VOL FACTO 1.01%
VHT VANGUARD HEALTH CARE ETF 0.97%
XLF FINANCIAL SELECT SECTOR SPDR 0.90%

Recent Articles from TheStreet

Chinese Investors Mock Asset Managers And Offer Advice On Stock Picks For Cautious Approach To Renewables Sector

Stocks May Drop 20% as Stimulus Eases, Growth Slows: Morgan Stanley

Stocks could drop 20% as fiscal stimulus is withdrawn and economic growth slows, a Morgan Stanley strategist says.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Stock Rises on Progress With Breast-Cancer Treatment

AstraZeneca's breast-cancer treatment reduced the risk of disease progression or death by 72% vs. a currently approved treatment.

Cryptocurrency Lead

Cryptocurrency Price Check: Bitcoin Tumbles on Evergrande Woes

Bitcoin and other cryptocurrencies are battered as China Evergrande Group struggles with bond obligations.

China Aims To Strengthen Its Semiconductor Supply Chain With New Standards Group That Includes Huawei, SMIC

Brooks Automation Stock Jumps on Plan to Sell Chip Solutions Unit for $3B

Brooks Automation is selling its chip solutions group and said it would no longer pursue splitting into two companies.

DR Horton, Verizon, HCA Holdings Top Analysts' Actions Monday

DR Horton Trims 2021 Sales Forecast Amid Supply Chain Disruptions

DR Horton said "significant disruptions in the supply chain ... along with tightness in the labor market" will lead to a modestly lower full-year sales forecast.

11. Colgate-Palmolive

Colgate-Palmolive Underappreciated, Deutsche Bank Says, Lifting to Buy

Colgate-Palmolive stock was upgraded to buy with an $86 price target at Deutsche Bank.

Watch Jim Cramer Live 9/20

Video: Jim Cramer on the Market Selloff, Evergrande, Debt Ceiling, Fed, Pfizer

Jim Cramer discusses the market selloff, Evergrande, debt ceiling talks, the upcoming Federal Reserve meeting, Pfizer and more in his latest video interview with TheStreet.

Wynn Lead

Wynn Resorts 'Worth Risk' of Macau Restrictions, Morgan Stanley Says

Wynn Resorts faces regulatory uncertainty in Macau, but Morgan Stanley says the casino operator is still 'worth the risk.'

Chinese Tesla Challenger Xpeng Prices Its P5 Sedan From US$24,700 After Subsidies As Battle For EV Buyers Intensifies

Tesla Wider Self-Driving Effort Reportedly Opposed by NTSB Chief

Tesla wants to expand its autonomous-driving effort to help cars make their way through cities, not just highways.

BioNTech and Pfizer's mRNA-based vaccine candidate BNT162b2 has proven to be more than 90 per cent effective in preventing Covid-19 infections. Photo: Reuters

Premarket Movers Monday - Pfizer, Netflix, Li Auto, AstraZeneca

Stocks moving in premarket trading Monday include Pfizer, Netflix, Li Auto, AstraZeneca and Bank of America.